Manuel Valladares

First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study

Eduardo Díaz‐Rubio, Auxiliadora Gómez‐España, Bartomeu Massutí et al. · The Oncologist · 2012 · 212 citations · Full text

Medicine, Oncology, Pharmacology +12

Irinotecan in Combination With Fluorouracil in a 48-Hour Continuous Infusion As First-Line Chemotherapy for Elderly Patients With Metastatic Colorectal Cancer: A Spanish Cooperative Group for the Treatment of Digestive Tumors Study

Javier Sastre, Eugenio Marcuello, B. Masutti et al. · Journal of Clinical Oncology · 2005 · 98 citations

Medicine, Oncology, Pharmacotherapy +15

Circulating Tumor Cell Count Is a Prognostic Factor in Metastatic Colorectal Cancer Patients Receiving First-Line Chemotherapy Plus Bevacizumab: A Spanish Cooperative Group for the Treatment of Digestive Tumors Study

Javier Sastre, M.L. Maestro, Auxiliadora Gómez‐España et al. · The Oncologist · 2012 · 88 citations · Full text

Medicine, Oncology, Pharmacology +17

miR-203 Regulates Cell Proliferation through Its Influence on Hakai Expression

Vanessa Abella, Manuel Valladares, T Veliz Rodriguez et al. · PLoS ONE · 2012 · 41 citations · Full text

Life Sciences, Cell Biology, Oncology +17

First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study

Eduardo Díaz‐Rubio, Auxiliadora Gómez‐España, Bartomeu Massutí et al. · 2012 · 25 citations

Medicine, Oncology, Pharmacology +12